Cebranopadol, a Novel First-in-Class Analgesic Drug Candidate: First Experience With Cancer-Related Pain for up to 26 Weeks.

MLA

Koch, E.Dietlind, et al. “Cebranopadol, a Novel First-in-Class Analgesic Drug Candidate: First Experience With Cancer-Related Pain for up to 26 Weeks.” Journal of Pain & Symptom Management, vol. 58, no. 3, Sept. 2019, pp. 390–99. EBSCOhost, https://doi.org/10.1016/j.jpainsymman.2019.05.012.

APA

Koch, E. D., Kapanadze, S., Eerdekens, M.-H., Kralidis, G., Létal, J., Sabatschus, I., & Ahmedzai, S. H. (2019). Cebranopadol, a Novel First-in-Class Analgesic Drug Candidate: First Experience With Cancer-Related Pain for up to 26 Weeks. Journal of Pain & Symptom Management, 58(3), 390–399. https://doi.org/10.1016/j.jpainsymman.2019.05.012

Chicago

Koch, E. Dietlind, Sofia Kapanadze, Marie-Henriette Eerdekens, Georg Kralidis, Jiří Létal, Ingo Sabatschus, and Sam H. Ahmedzai. 2019. “Cebranopadol, a Novel First-in-Class Analgesic Drug Candidate: First Experience With Cancer-Related Pain for up to 26 Weeks.” Journal of Pain & Symptom Management 58 (3): 390–99. doi:10.1016/j.jpainsymman.2019.05.012.